# Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients

> **NCT02462265** · PHASE2 · SUSPENDED · sponsor: **Oshadi Drug Administration** · enrollment: 15 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Lymphoid Leukemia

## Interventions

- **DRUG:** Oshadi D & Oshadi R;
- **DRUG:** salvage therapy cytosar and mitoxantrone

## Key facts

- **NCT ID:** NCT02462265
- **Lead sponsor:** Oshadi Drug Administration
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2017-01
- **Primary completion:** 2018-06
- **Final completion:** 2018-12
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2018-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02462265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02462265, "Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02462265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*